Episurf Medical (STO:EPISB) (NASDAQ:EPISB), a provider of minimally invasive and individualised treatment alternatives for people with painful joint injuries, revealed on Friday that it expects to receive CE marking for the Episealer Talus ankle implant very soon.

The review process for obtaining the CE mark for Episealer Talus has now been concluded and the final formal process for issuing the CE certificate is expected to be completed within the next two weeks.

The implant is intended for osteochondral lesions of the talar dome of the ankle joint. It is based on the same technology platform as the company's Episealer knee devices, with an individualised design based on medical imaging and 3D modulation.

Episurf Medical has also applied for CE marking for an individualised osteotomy guide that is intended to help surgeons to find the correct position and depth of sawing when performing a medial malleolar osteotomy.